Who is sponsoring NCT03746639?

NCT03746639 is sponsored by Alper Mengi.

What drugs are being tested in NCT03746639?

Interventions in NCT03746639: physiotherapy modalities.

What condition does NCT03746639 study?

NCT03746639 studies Ultrasound Therapy; Complications, Low Back Pain.

Is NCT03746639 still recruiting?

NCT03746639 is currently completed. Last updated 27 November 2018.

Last reviewed 2018-11-27 · How we verify

NCT03746639

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Therapeutic Ultrasound on Renal Function

Completed NA Last updated 27 November 2018

What this trial tests

NA trial testing physiotherapy modalities in Ultrasound Therapy; Complications in 40 participants. Completed in 14 November 2018.

Timeline

1 January 2016

Primary endpoint
31 December 2017

14 November 2018

Quick facts

Lead sponsor	Alper Mengi
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	40
Start date	1 January 2016
Primary completion	31 December 2017
Estimated completion	14 November 2018

Drugs / interventions tested

physiotherapy modalities

Conditions studied

Ultrasound Therapy; Complications — all drugs for Ultrasound Therapy; Complications →
Low Back Pain — all drugs for Low Back Pain →

Sponsor

Alper Mengi

Who can join

Adults 18 to 65, any sex, with Ultrasound Therapy; Complications or Low Back Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates whether therapeutic ultrasound (TUS) treatment applied to lumbar region with chronic low back pain affect renal function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ultrasound Therapy; Complications

Currently open trials in the same condition.

NCT06955221 — Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis · NA · recruiting
NCT05778279 — Role of New High Resolution Ultrasonographic Modalities for Diagnosis of Fetal Nervous System Anomalies · recruiting
NCT06264167 — NODE (groiN ultrasOunD cancEr) · NA · recruiting
NCT06241716 — Ultrasound-assisted Versus Real-time Ultrasound-guided Combined Spinal-epidural Anesthesia in Elderly Patients · NA · recruiting
NCT05769517 — Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries · recruiting

Other Alper Mengi trials

Trials by the same sponsor.

NCT03314285 — Evaluation of Sleep Quality in Patients With Chronic Neck Pain · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03746639 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alper Mengi
Last refreshed: 27 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03746639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing